The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity
Open accessAbstract
Non-steroidal anti-inflammatory agents (NSAIDs) are associated with a marked reduction in the risk of developing Alzheimer's disease, a form of dementia characterized by the accumulation of amyloid plaques containing the amyloid-beta protein (Abeta). Studies of the effects of NSAIDs upon the inflammatory response surrounding amyloid plaques and upon the generation of Abeta from the amyloid precursor protein (APP) have led to two proposed mechanisms by which NSAIDs may protect against Alzheimer's disease: one, the selective lowering of Abeta42 by a subset of NSAIDs; and two, the reduction of inflammation. Although Alzheimer's disease is a disorder of brain and synaptic function, the effects of NSAIDs on Abeta-mediated suppression of synaptic plasticity and memory function have never been reported. We therefore investigated how three different NSAIDs, chosen for their distinct effects on Abeta42 production and the inhibition of the cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, affect memory function and synaptic plasticity. By focusing upon brain and synapse function, we made novel observations about the effects of NSAIDs on Abeta-mediated neural processes. Here we report that the selective inhibition of COX-2, but not COX-1, acutely prevented the suppression of hippocampal long-term plasticity (LTP) by Abeta. The non-selective NSAIDs, ibuprofen and naproxen, and a selective COX-2 inhibitor, MF-tricyclic, each restored memory function in Tg2576 mice over-expressing APP, and also blocked Abeta-mediated inhibition of LTP. There was no advantage of ibuprofen, a selective Abeta42-lowering agent (SALA), over the non-SALAs, naproxen and MF-tricyclic. The beneficial effects on memory did not depend upon lowered levels of Abeta42 or the inflammatory cytokines, tumour necrosis factor alpha (TNF-alpha) and interleukin 1beta (IL-1beta). Intriguingly, improved memory function was inversely related to prostaglandin E2 (PGE2) levels. Conversely, exogenous PGE2 prevented the restorative effects of COX-2 inhibitors on LTP. The data indicate that the inhibition of COX-2 blocks Abeta-mediated suppression of LTP and memory function, and that this block occurs independently of reductions in Abeta42 or decreases in inflammation. The results lead us to propose a third possible mechanism by which NSAIDs may protect against Alzheimer's disease, involving the blockade of a COX-2-mediated PGE2 response at synapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 8×
“Ab à 56 was measured in membrane-enriched extracts of hemibrains following a four-step extraction procedure, by immunoblotting using the 6E10 monoclonal antibody (Lesné et al., 2006).”
InfluentialSelf-citationRetractedWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Self-citationReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 7×
“This COXindependent activity has been proposed as an alternative explanation to anti-inflammation as the mechanism by which NSAIDs exert their neuroprotective effects (Weggen et al., 2001).”
InfluentialNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 1×
“It has been suggested that NSAIDs protect against Alzheimer’s disease by reducing proinflammatory cytokine production by inhibiting COX or activating PPAR-γ (Lehmann et al., 1997; Combs et al., 2000).”
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 4×
“In addition, both soluble and fibrillar Ab levels remained 4100 times higher than those evaluated in Tg mice56 months of age, prior to the onset of memory loss (Kawarabayashi et al., 2001).”
InfluentialSelf-citationSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
Cited by
Immune modulation of learning, memory, neural plasticity and neurogenesis
Yirmiya, R., & Goshen, I. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.015 · Cited by 1,483
Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
Neuroinflammation: The role and consequences
Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., & Ma, D. (2014) · Neuroscience Research · doi:10.1016/j.neures.2013.10.004 · Cited by 730
Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response
Bachiller, S., Jiménez-Ferrer, I., Paulus, A., Yang, Y., Swanberg, M., Deierborg, T., & Boza-Serrano, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00488 · Cited by 707
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432
“Long-term use of NSAIDs is also associated with protection from the development of AD and reduction in Ab deposition in mouse models of AD and is positively correlated with reduction of plaque-associated microglia in both humans and mice [78-82].”
BackgroundProbing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
Self-citationInflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
“Of note, two selective cyclooxygenase-2 (COX-2) inhibitors are found to be effective in rescuing LTP impairment by synthetic soluble Aβ1−42, whereas the same effect is not achieved with the cyclooxygenase-1 (COX-1) inhibitor piroxicam (154).”
BackgroundInflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease
Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & De Felice, F. G. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 356
Extended results of the Alzheimer's disease anti‐inflammatory prevention trial
Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, J., Craft, S., Evans, D. E., Green, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.014 · Cited by 328
Self-citationAlzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 326
Targeting Astrocytes Ameliorates Neurologic Changes in a Mouse Model of Alzheimer's Disease
Furman, J. L., Sama, D. M., Gant, J. C., Beckett, T. L., Murphy, M. P., Bachstetter, A. D., Van Eldik, L. J., & Norris, C. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2323-12.2012 · Cited by 313
Aβ1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β
Jo, J., Whitcomb, D. J., Olsen, K. M., Kerrigan, T. L., Lo, S.-C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2785 · Cited by 305
Omega-3 fatty acids and dementia
Cole, G. M., Ma, Q.-L., & Frautschy, S. A. (2009) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2009.05.015 · Cited by 269
Self-citationPiro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., Schwartz, J. W., Nomura, D. K., & Samad, T. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.05.001 · Cited by 223
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121
Medeiros, R., Figueiredo, C. P., Pandolfo, P., Duarte, F. S., Prediger, R. D. S., Passos, G. F., & Calixto, J. B. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.01.040 · Cited by 121
Parthsarathy, V., & Hölscher, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.012 · Cited by 119
Chen, X., Lin, R., Chang, L., Xu, S., Wei, X., Zhang, J., Wang, C., Anwyl, R., & Wang, Q. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.054 · Cited by 93
Self-citationKamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., S, S., Singh S, A., & Prajapati, B. G. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.005 · Cited by 90
Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy
Lee, J. Y., Jin, H. K., & Bae, J.-S. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.278 · Cited by 80
Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment
Imbimbo (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00019 · Cited by 75
Zheng, Y., Zhang, X., Zhang, R., Wang, Z., Gan, J., Gao, Q., Yang, L., Xu, P., & Jiang, X. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5314 · Cited by 52
Lin, N., Pan, X.-D., Chen, A.-Q., Zhu, Y.-G., Wu, M., Zhang, J., & Chen, X.-C. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.10.010 · Cited by 48
Ibuprofen modifies cognitive disease progression in an Alzheimer’s mouse model
Van Dam, D., Coen, K., & De Deyn, P. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108097630 · Cited by 45
Lobine, D., Sadeer, N., Jugreet, S., Suroowan, S., Keenoo, B. S., Imran, M., Venugopala, K. N., Ibrahim, F. M., Zengin, G., & Mahomoodally, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210412095251 · Cited by 32
Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers
Brazier, D., Perry, R., Keane, J., Barrett, K., & Elmaleh, D. R. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0549-5 · Cited by 31
Calderón-Garcidueñas, L., Mora-Tiscareño, A., Gómez-Garza, G., Carrasco-Portugal, M. D. C., Pérez-Guillé, B., Flores-Murrieta, F. J., Pérez-Guillé, G., Osnaya, N., Juárez-Olguín, H., Monroy, M. E., et al. (2009) · Toxicologic Pathology · doi:10.1177/0192623309340277 · Cited by 28
Ayoub, S. S., Wood, E. G., Hassan, S.-U., & Bolton, C. (2011) · Inflammation Research · doi:10.1007/s00011-011-0352-3 · Cited by 19
Herbal medicine for psychiatric disorders: Psychopharmacology and neuroscience-based nomenclature
Tang, S. W., Tang, W. H., & Leonard, B. E. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1346279 · Cited by 11
Metadata
- Authors
- Kotilinek, L. A., Westerman, M. A., Wang, Q., Panizzon, K., Lim, G. P., Simonyi, A., Lesne, S., Falinska, A., Younkin, L. H., Younkin, S. G., Rowan, M., Cleary, J., Wallis, R. A., Sun, G. Y., Cole, G., Frautschy, S., Anwyl, R., & Ashe, K. H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03
- Volume
- 131
- Issue
- 3
- Pages
- 651-664
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2150356698
- Cited by
- 220
- References
- 25
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.